Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 677Neoplasms 593Colorectal Neoplasms 292Carcinoma, Non-Small-Cell Lung 292Prostatic Neoplasms 281Lung Neoplasms 223Melanoma 161Multiple Myeloma 150Neoplasm Metastasis 146Head and Neck Neoplasms 143Pancreatic Neoplasms 141Ovarian Neoplasms 133Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 123Colonic Neoplasms 112Brain Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 108Stomach Neoplasms 105Recurrence 101Lymphoma 101Glioblastoma 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 82Lymphoma, Non-Hodgkin 82Hematologic Neoplasms 80Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Glioma 75Parkinson Disease 4, Autosomal Dominant Lewy Body 74Leukemia, Lymphocytic, Chronic, B-Cell 72

Interventions

larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumors Harboring NTRK Fusion × 1 year × Clear all
NCT02122913 2026-02-05

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Bayer

Phase 1 Completed
75 enrolled 2 FDA
Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡